NC
CLSD

Northpointe Capital’s Clearside Biomedical CLSD Stock Holding History

Northpointe Capital’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-37,517
Closed -$602K – 101
2018
Q4 		$602K Sell
37,517
-8,302
-18% -$390K 0.14% 163
2018
Q3 		$4.23M Sell
45,819
-8,590
-16% -$1.02M 0.61% 65
2018
Q2 		$8.72M Buy
+54,409
New +$9.17M 1.16% 16

Other funds holding CLSD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Northpointe Capital's CLSD Position: Q1 2019 in Review

Northpointe Capital sold out of Clearside Biomedical (CLSD) in Q1 2019, closing a stake of 37,517 shares — an estimated $602K sold.

Northpointe Capital first reported a position in CLSD in Q2 2018 and held it in 3 quarters. The position peaked at $8.72M in Q2 2018. 57 funds tracked by Wall St. Rank hold CLSD as of Q1 2019.

  • Northpointe Capital reported no remaining Clearside Biomedical position as of Q1 2019 after selling out during the quarter.
  • Northpointe Capital sold 37,517 Clearside Biomedical shares in Q1 2019, an estimated $602K.
  • Northpointe Capital first reported a position in Clearside Biomedical in Q2 2018 and held it in 3 quarters.
  • Northpointe Capital's Clearside Biomedical position peaked at $8.72M in Q2 2018.
  • 57 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2019.

Based on Northpointe Capital's 13F filing for Q1 2019, filed 17 Apr 2019.